{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.', 'PROCEDURES', 'The following procedures will be conducted as outlined in the Table of Events, Table 3.', '6.1.', 'Screening Period', 'Screening evaluations will be performed for all subjects to determine study eligibility. These', 'evaluations must be completed within 5 weeks of randomization. Subjects who do not meet', 'eligibility criteria for the study may be re-screened once, after a minimum of 35 days from the', 'date of their first screening.', 'Waivers to the protocol will not be granted during the conduct of this trial, under any', 'circumstances.', 'Safety laboratory analyses and all assessments will be performed (locally/centrally). Screening', 'laboratory values must demonstrate subject eligibility, but may be repeated once within the', 'screening window, if necessary.', 'The following will be performed at screening as specified in the Table of Events, after informed', 'consent has been obtained:', 'Demographics (year of birth, sex, and race, if allowed by local regulations, will be', 'collected).', 'Complete medical history', 'Prior and concomitant medications', 'Physical examination, height, weight, waist circumference, body mass index (see', 'Appendix O)', 'Vital signs (including blood pressure and heart rate)', 'Hematology panel including complete blood count (CBC) with differential, including red', 'blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH),', 'mean corpuscular hemoglobin concentration (MCHC), RBC Morphology, mean', 'corpuscular volume (MCV), white blood cell (WBC) count (with differential), and', 'platelet count.', 'Chemistry panel including sodium, potassium, calcium, chloride, blood urea nitrogen', '(BUN), creatinine, creatinine clearance, glucose, albumin, total protein, alkaline', 'phosphatase, bilirubin (total and direct), aspartate aminotransferase/serum glutamic', 'oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic', 'transaminase (ALT/SGPT), gamma-glutamyl transferase (GGT), lactate dehydrogenase', '(LDH). A lipid panel will be included in the standard chemistry panel.', 'Pregnancy test is required for all female subjects of childbearing potential. Serum beta', 'human chorionic gonadotropin (B-hCG) pregnancy test will be performed at screening.', 'Urine (or serum) pregnancy test will be performed to assess subject eligibility within 72', 'Confidential and Proprietary', '32', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'hours prior to the first administration of IP, if the initial serum pregnancy test did not', 'already occur with 72 hours of dosing (negative results required for IP administration).', 'Contraception education will be performed by the Investigator at screening for all FCBP', 'about the options for and correct use of contraceptive methods at the Screening and', \"Baseline Visits and at any time when a FCBP's contraceptive measures or ability to\", 'become pregnant changes.', '-', 'A pregnancy test should be performed if the FCBP subject has missed a menstrual', 'period or the contraception method has changed', '- Counseling about pregnancy precautions and the potential risks of fetal exposure', 'must be conducted.', 'Adverse event assessment begins when the subject signs the informed consent form', 'Health-related quality of life and efficacy assessments to determine study eligibility,', 'including DLQI, sPGA of visible locations, ScPGA, NAPSI, modified sPGA-G, PPPGA,', 'and PASI', '6.2.', 'Treatment Period', 'The subject will begin treatment upon confirmation of eligibility. The subject must start', 'treatment within 35 days (5 weeks) of signing the ICF. An administrative window of 3 day is', 'permitted for Visits 3 and 4 and 4 days is permitted for Visits 5 through 9.', 'The following procedures will be conducted as outlined in the Table of Events, Table 3. The', 'evaluations should be performed prior to dosing on the visit day, unless otherwise specified.', 'Inclusion/Exclusion criteria (Baseline/Visit 2)', 'Concomitant medications and therapies evaluation', 'Vital signs', 'Weight, waist circumference', 'Adverse event evaluation (continuously and through 28 days after last dose of', 'apremilast)', 'Clinical laboratory evaluations [If screening laboratory assessments are within 7 days', 'of Baseline (Week 0), laboratory assessment does not need to be repeated at Baseline', '(Week 0)]', 'Efficacy assessment (see Section 6.4) [In addition to assessments specified in Table 3,', 'investigator will follow country guidelines to monitor therapy outcomes according to', 'clinical routine care and may assess efficacy or safety at any unscheduled visit and', 'document in source documents.]', 'Dispense IP', 'Return and count IP tablets', 'Urine (or serum) pregnancy test (prior to dosing on Day 1)', 'Confidential and Proprietary', '33', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}